Cargando…

EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Emerging evidence indicates that Fascin-1 (FSCN1) may possess a causal role in the development of several types of cancers and serves as a novel biomarker of aggressiveness in certain carcinomas. However, the regulatory mechanism of FSCN1 in triple-negative breast cancer (TNBC) cell invasion and mig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Chao-Qun, Li, Yang, Huang, Bi-Fei, Zhao, Yong-Ming, Yuan, Hui, Guo, Dongfang, Su, Chen-Ming, Hu, Gui-Nv, Wang, Qian, Long, Tengyun, Wang, Yan, Tang, Chih-Hsin, Li, Xiaoni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688137/ https://www.ncbi.nlm.nih.gov/pubmed/29142206 http://dx.doi.org/10.1038/s41598-017-15939-9

Ejemplares similares

FSCN1 gene polymorphisms: biomarkers for the development and progression of breast cancer
por: Wang, Chao-Qun, et al.
Publicado: (2017)

Fascin‐1 as a novel diagnostic marker of triple‐negative breast cancer
por: Wang, Chao‐Qun, et al.
Publicado: (2016)

Impacts of RETN genetic polymorphism on breast cancer development
por: Wang, Chao-Qun, et al.
Publicado: (2020)

FSCN1 Promotes Radiation Resistance in Patients With PIK3CA Gene Alteration
por: Li, Sisi, et al.
Publicado: (2021)

Prognostic significance of FSCN family in multiple myeloma
por: Deng, Cong, et al.
Publicado: (2021)

MiR-24 functions as a tumor suppressor in nasopharyngeal carcinoma through targeting FSCN1
por: Li, Ying-Qing, et al.
Publicado: (2015)

Upregulated WTAP expression appears to both promote breast cancer growth and inhibit lymph node metastasis
por: Wang, Chao-Qun, et al.
Publicado: (2022)

The impact of Angiopoietin-2 genetic polymorphisms on susceptibility for malignant breast neoplasms
por: Hu, Gui-Nv, et al.
Publicado: (2022)

HMGB1 genetic polymorphisms are biomarkers for the development and progression of breast cancer
por: Huang, Bi-Fei, et al.
Publicado: (2018)

Lack of epidermal growth factor receptor (EGFR)-activating mutations in triple-negative breast cancer in China
por: Cao, Wen-Ming, et al.
Publicado: (2015)

Significance of BMI1 and FSCN1 Expression in Colorectal Cancer
por: Alajez, Nehad M.
Publicado: (2016)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Downregulated METTL14 Expression Correlates with Breast Cancer Tumor Grade and Molecular Classification
por: Dong, Xiao-Fang, et al.
Publicado: (2020)

miR-539 inhibits FSCN1 expression and suppresses hepatocellular carcinoma migration and invasion
por: Liu, Yanping, et al.
Publicado: (2017)

SOX2 Promotes Brain Metastasis of Breast Cancer by Upregulating the Expression of FSCN1 and HBEGF
por: Xiao, Weikai, et al.
Publicado: (2020)

miR-145 Contributes to the Progression of Cervical Carcinoma by Directly Regulating FSCN1
por: Ma, Li, et al.
Publicado: (2019)

Comprehensive analysis of the expression, prognosis and biological significance of FSCN family in clear cell renal cell carcinoma
por: Lin, Yongping, et al.
Publicado: (2023)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer
por: Jiang, Weihua, et al.
Publicado: (2020)

p-STAT3 expression in breast cancer correlates negatively with tumor size and HER2 status
por: Wang, Yan, et al.
Publicado: (2021)

Combined High Resistin and EGFR Expression Predicts a Poor Prognosis in Breast Cancer
por: Zeng, Yue, et al.
Publicado: (2020)

LYAR Promotes Colorectal Cancer Progression by Upregulating FSCN1 Expression and Fatty Acid Metabolism
por: Wu, Yupeng, et al.
Publicado: (2021)

Correlation between CCL4 gene polymorphisms and clinical aspects of breast cancer
por: Hu, Gui-Nv, et al.
Publicado: (2018)

Reverse Correlation between MicroRNA-145 and FSCN1 Affecting Gastric Cancer Migration and Invasion
por: Chen, Jia-jia, et al.
Publicado: (2015)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Targeting FSCN1 with an oral small-molecule inhibitor for treating ocular neovascularization
por: Bai, Wen, et al.
Publicado: (2023)

Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis
por: Zhang, Li, et al.
Publicado: (2015)

Analysis of CK5/6 and EGFR and Its Effect on Prognosis of Triple Negative Breast Cancer
por: Wang, Zhen, et al.
Publicado: (2021)

Fscn1 is required for the trafficking of TGF-β family type I receptors during endoderm formation
por: Liu, Zhaoting, et al.
Publicado: (2016)

Molecular characteristics of recurrent triple-negative breast cancer
por: TSAI, CHUNG-HSIN, et al.
Publicado: (2015)

Targeting YAP1/LINC00152/FSCN1 Signaling Axis Prevents the Progression of Colorectal Cancer
por: Ou, Chunlin, et al.
Publicado: (2019)

FSCN1 is an effective marker of poor prognosis and a potential therapeutic target in human tongue squamous cell carcinoma
por: Chen, Yue, et al.
Publicado: (2019)

FSCN1 Promotes Glycolysis and Epithelial-Mesenchymal Transition in Prostate Cancer through a YAP/TAZ Signaling Pathway
por: Li, Minghui, et al.
Publicado: (2022)

Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients
por: Liang, Jiayu, et al.
Publicado: (2019)

MicroRNA-488 inhibits proliferation and motility of tumor cells via downregulating FSCN1, modulated by Notch3 in breast carcinomas
por: Wu, Yang, et al.
Publicado: (2020)

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
por: Linklater, Erik S., et al.
Publicado: (2016)

Transcriptome analysis reveals the potential biological function of FSCN1 in HeLa cervical cancer cells
por: Guo, Fengqin, et al.
Publicado: (2022)

Using next‐generation sequencing to redefine BRCAness in triple‐negative breast cancer
por: Lin, Po‐Han, et al.
Publicado: (2020)

SYTL2 promotes metastasis of prostate cancer cells by enhancing FSCN1-mediated pseudopodia formation and invasion
por: Li, Zean, et al.
Publicado: (2023)

ADORA2A-AS1 Restricts Hepatocellular Carcinoma Progression via Binding HuR and Repressing FSCN1/AKT Axis
por: Pu, Jian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rkkefrtrrljo4av7n34o13n0mc